Anhui Huaheng Biotechnology Co. Ltd. A (688639) - Net Assets
Based on the latest financial reports, Anhui Huaheng Biotechnology Co. Ltd. A (688639) has net assets worth CN¥2.67 Billion CNY (≈ $390.54 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.03 Billion ≈ $881.78 Million USD) and total liabilities (CN¥3.36 Billion ≈ $491.24 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Anhui Huaheng Biotechnology Co. Ltd. A tangible book value ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥2.67 Billion |
| % of Total Assets | 44.29% |
| Annual Growth Rate | 56.49% |
| 5-Year Change | 122.45% |
| 10-Year Change | 1393.21% |
| Growth Volatility | 56.05 |
Anhui Huaheng Biotechnology Co. Ltd. A - Net Assets Trend (2012–2025)
This chart illustrates how Anhui Huaheng Biotechnology Co. Ltd. A's net assets have evolved over time, based on quarterly financial data. See operational self-sufficiency of Anhui Huaheng Biotechnology Co. Ltd. A to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Anhui Huaheng Biotechnology Co. Ltd. A (2012–2025)
The table below shows the annual net assets of Anhui Huaheng Biotechnology Co. Ltd. A from 2012 to 2025. For live valuation and market cap data, see 688639 stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥2.63 Billion ≈ $385.12 Million |
+2.87% |
| 2024-12-31 | CN¥2.56 Billion ≈ $374.37 Million |
+40.13% |
| 2023-12-31 | CN¥1.83 Billion ≈ $267.15 Million |
+23.22% |
| 2022-12-31 | CN¥1.48 Billion ≈ $216.81 Million |
+25.23% |
| 2021-12-31 | CN¥1.18 Billion ≈ $173.13 Million |
+141.56% |
| 2020-12-31 | CN¥489.78 Million ≈ $71.67 Million |
+32.85% |
| 2019-12-31 | CN¥368.68 Million ≈ $53.95 Million |
+18.82% |
| 2018-12-31 | CN¥310.29 Million ≈ $45.41 Million |
+47.25% |
| 2017-12-31 | CN¥210.73 Million ≈ $30.84 Million |
+19.56% |
| 2016-12-31 | CN¥176.26 Million ≈ $25.79 Million |
+53.99% |
| 2015-12-31 | CN¥114.46 Million ≈ $16.75 Million |
+111.59% |
| 2014-12-31 | CN¥54.10 Million ≈ $7.92 Million |
+164.46% |
| 2013-12-31 | CN¥20.46 Million ≈ $2.99 Million |
+162.19% |
| 2012-12-31 | CN¥7.80 Million ≈ $1.14 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Anhui Huaheng Biotechnology Co. Ltd. A's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 113992295191.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥1.14 Billion | 42.99% |
| Common Stock | CN¥250.12 Million | 9.45% |
| Other Comprehensive Income | CN¥41.12 Million | 1.55% |
| Other Components | CN¥1.22 Billion | 46.01% |
| Total Equity | CN¥2.65 Billion | 100.00% |
Anhui Huaheng Biotechnology Co. Ltd. A Competitors by Market Cap
The table below lists competitors of Anhui Huaheng Biotechnology Co. Ltd. A ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
INKON Life Technology Co Ltd
SHE:300143
|
$764.39 Million |
|
Hextar Global Bhd
KLSE:5151
|
$764.64 Million |
|
Quanex Building Products
NYSE:NX
|
$764.70 Million |
|
Niutech Environment Technology Corp
SHG:688309
|
$764.87 Million |
|
Beijing SL Pharmaceutical Co Ltd
SHE:002038
|
$763.69 Million |
|
Risesun Real Estate Development Co Ltd
SHE:002146
|
$763.53 Million |
|
Jdd Tech New Mat Co Ltd
SHE:301538
|
$763.37 Million |
|
Replimune Group Inc
NASDAQ:REPL
|
$762.97 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Anhui Huaheng Biotechnology Co. Ltd. A's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 2,564,649,586 to 2,646,682,105, a change of 82,032,519 (3.2%).
- Net income of 132,412,138 contributed positively to equity growth.
- Dividend payments of 110,813,237 reduced retained earnings.
- Other comprehensive income increased equity by 41,122,053.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥132.41 Million | +5.0% |
| Dividends Paid | CN¥110.81 Million | -4.19% |
| Other Comprehensive Income | CN¥41.12 Million | +1.55% |
| Other Changes | CN¥19.31 Million | +0.73% |
| Total Change | CN¥- | 3.20% |
Book Value vs Market Value Analysis
This analysis compares Anhui Huaheng Biotechnology Co. Ltd. A's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.98x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 579.67x to 1.98x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2012-12-31 | CN¥0.04 | CN¥20.87 | x |
| 2013-12-31 | CN¥0.18 | CN¥20.87 | x |
| 2014-12-31 | CN¥0.98 | CN¥20.87 | x |
| 2015-12-31 | CN¥1.44 | CN¥20.87 | x |
| 2016-12-31 | CN¥2.20 | CN¥20.87 | x |
| 2017-12-31 | CN¥1.25 | CN¥20.87 | x |
| 2018-12-31 | CN¥1.84 | CN¥20.87 | x |
| 2019-12-31 | CN¥2.16 | CN¥20.87 | x |
| 2020-12-31 | CN¥2.89 | CN¥20.87 | x |
| 2021-12-31 | CN¥5.69 | CN¥20.87 | x |
| 2022-12-31 | CN¥6.51 | CN¥20.87 | x |
| 2023-12-31 | CN¥7.97 | CN¥20.87 | x |
| 2024-12-31 | CN¥11.10 | CN¥20.87 | x |
| 2025-12-31 | CN¥10.52 | CN¥20.87 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Anhui Huaheng Biotechnology Co. Ltd. A utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 5.00%
- The company has moderate efficiency in generating returns from equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 4.63%
- • Asset Turnover: 0.50x
- • Equity Multiplier: 2.18x
- Recent ROE (5.00%) is below the historical average (22.63%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2012 | -48.67% | -4.38% | 0.69x | 16.14x | CN¥-4.58 Million |
| 2013 | 63.55% | 7.50% | 0.94x | 9.04x | CN¥10.95 Million |
| 2014 | 42.49% | 10.22% | 1.18x | 3.51x | CN¥17.58 Million |
| 2015 | 37.39% | 16.89% | 0.88x | 2.53x | CN¥31.35 Million |
| 2016 | 35.06% | 19.84% | 0.81x | 2.19x | CN¥44.17 Million |
| 2017 | 30.80% | 16.96% | 0.93x | 1.96x | CN¥43.82 Million |
| 2018 | 24.33% | 17.94% | 0.78x | 1.74x | CN¥44.48 Million |
| 2019 | 34.28% | 25.72% | 0.88x | 1.52x | CN¥89.51 Million |
| 2020 | 24.73% | 24.85% | 0.66x | 1.52x | CN¥72.12 Million |
| 2021 | 14.22% | 17.63% | 0.65x | 1.25x | CN¥49.92 Million |
| 2022 | 21.62% | 22.56% | 0.70x | 1.37x | CN¥171.98 Million |
| 2023 | 24.58% | 23.17% | 0.49x | 2.17x | CN¥266.36 Million |
| 2024 | 7.39% | 8.70% | 0.44x | 1.95x | CN¥-66.95 Million |
| 2025 | 5.00% | 4.63% | 0.50x | 2.18x | CN¥-132.26 Million |
Industry Comparison
This section compares Anhui Huaheng Biotechnology Co. Ltd. A's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $604,930,526
- Average return on equity (ROE) among peers: 13.07%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Anhui Huaheng Biotechnology Co. Ltd. A (688639) | CN¥2.67 Billion | -48.67% | 1.26x | $763.84 Million |
| Shenzhen CAU Technology Co Ltd (000004) | $85.02 Million | 26.56% | 2.79x | $53.47 Million |
| Pacific Shuanglin Bio pharmacy Co Ltd (000403) | $64.35 Million | 12.98% | 2.10x | $1.50 Billion |
| Nanhua Bio Medicine Co Ltd (000504) | $128.43 Million | -28.90% | 2.15x | $378.62 Million |
| Jiangsu Sihuan Bioengineering Co Ltd (000518) | $730.78 Million | -9.68% | 0.13x | $470.05 Million |
| Chengzhi Shareholding Co Ltd (000990) | $1.65 Billion | 1.65% | 0.84x | $1.54 Billion |
| Hualan Biological EngineeringInc (002007) | $94.10 Million | 30.66% | 1.57x | $3.43 Billion |
| Da An Gene Co Ltd of Sun Yat-Sen University (002030) | $626.21 Million | 14.40% | 0.46x | $1.14 Billion |
| Shanghai RAAS Blood Products Co Ltd Class A (002252) | $170.01 Million | 48.10% | 0.80x | $4.52 Billion |
| Baolingbao Biology Co Ltd (002286) | $238.05 Million | 18.81% | 2.12x | $496.75 Million |
| Tibet Cheezheng Tibetan Medicine Co Ltd (002287) | $2.26 Billion | 16.10% | 0.32x | $1.64 Billion |
About Anhui Huaheng Biotechnology Co. Ltd. A
Anhui Huaheng Biotechnology Co., Ltd. engages in the research and development, production, and sale of bio-based products through bio-manufacturing in China and internationally. The company offers amino acid products, including the alanine series, L-valine, isoleucine, tryptophan, and arginine; vitamin products, such as D-calcium pantothenate, D-panthenol, and inositol; bio-based new material mon… Read more